Science 37

Science 37 is a clinical research company that runs direct-to-patient trial sites, letting patients participate from home, with a community provider, or at a traditional site. Its model pairs a proprietary technology platform with in-house medical and operational experts, research-grade nursing, and nationwide recruitment under centralized physician oversight, and its sites have repeatedly passed FDA inspection with no action indicated.

The company went public through a 2021 combination with LifeSci Acquisition II and was taken private by eMed in March 2024, when a completed tender offer made it a wholly-owned subsidiary. Led since January 2025 by chief executive Tyler Van Horn, Science 37 partners with sponsors such as Catalent on direct-to-patient medicine logistics and publishes site-performance research with groups including the Tufts Center for the Study of Drug Development.